Endo Sues Sandoz Over ANDA For Generic Opana

Law360, New York (August 25, 2008, 12:00 AM EDT) -- Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. have accused Sandoz Inc. of patent infringement in their latest suit to keep a generic version of painkiller Opana ER off the market.

In a complaint filed Friday in the U.S. District Court for the District of Delaware, Endo and Penwest claim Sandoz infringed the patent for Opana when it filed an abbreviated new drug application and Paragraph IV certification for the painkiller with the U.S. Food and Drug Administration.

Sandoz, the generics division of Novartis AG, notified the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.